Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Food manufacturers are trying to whip themselves up a forkful of the slimming trend — but nutrition experts aren’t giving them a good review.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

Lory Osborn says the Wegovy she was prescribed 15 months ago did more than help her lose 75 pounds — over a quarter of her ...

For Robert F. Kennedy Jr., the activist whom President-elect Donald Trump will nominate to serve as the secretary of health and human services, the solution to obesity in America – now at 40% of ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...